AstraZeneca globally withdraw sales Covid-19 vaccine due to surplus of updated vaccines; admits rare blood clot side-effect.
AstraZeneca has globally withdraw its Covid-19 vaccine citing a surplus of updated vaccines since the pandemic. The company stated, according to Reuters, that the development of multiple variant Covid-19 vaccines has led to an excess of available options, resulting in decreased demand for Vaxzevria, which is now discontinued in production and supply.
AstraZeneca Announces Decision to Globally Withdraw Sales of Covid-19 Vaccine
In a significant move, pharmaceutical giant AstraZeneca has announced its decision to globally withdraw sales of its Covid-19 vaccine. This decision comes amidst mounting concerns over rare but serious side effects associated with the vaccine, including blood clotting issues. With this abrupt halt in sales, countries relying on the AstraZeneca vaccine for their immunization campaigns face logistical challenges and uncertainty. The withdrawal underscores the delicate balance between public health concerns and the imperative to vaccinate populations against the ongoing pandemic. As the global vaccination effort continues, the ramifications of AstraZeneca’s decision reverberate throughout the healthcare community, prompting governments and health authorities to reassess their vaccine strategies and deployment plans.
Furthermore, AstraZeneca’s decision to globally withdraw sales of its Covid-19 vaccine amplifies the urgency for diversified vaccine procurement strategies and accelerated research and development efforts. Governments and health organizations must swiftly mobilize alternative vaccine options to fill the void left by the absence of the AstraZeneca vaccine. This situation also underscores the importance of transparent communication and robust regulatory oversight in addressing vaccine safety concerns and maintaining public trust in vaccination programs. As the global community navigates this evolving landscape, collaboration and solidarity remain paramount in overcoming the challenges posed by the pandemic and achieving widespread immunization against Covid-19.
Rare Blood Clot Side-Effect Acknowledged by AstraZeneca
UK pharmaceutical giant acknowledges rare blood clot side-effect of Covid vaccine in “very rare cases,” Daily Telegraph reports. Legal document submitted to High Court in London reveals AstraZeneca’s admission of potential link to Thrombosis with Thrombocytopenia Syndrome (TTS).
AstraZeneca’s Covishield: The Vaxzevria Variant
AstraZeneca’s Vaxzevria vaccine, produced by Serum Institute of India, sold as Covishield in India. Supreme Court petition seeks formation of medical expert panel to assess Covishield side effects.
Advocating for Compensation: Vishal Tiwari’s Plea
Advocate Vishal Tiwari filed the plea, urging the court to direct the Centre to set up a compensation system for citizens severely disabled by vaccination during the pandemic.
Advocate Vishal Tiwari’s plea requests the formation of a medical expert panel, led by the director of All India Institute of Medical Science, Delhi, and overseen by a retired Supreme Court justice, to assess Covishield vaccine side effects and risks.
Advocate Vishal Tiwari stated in the application that over 1.75 billion doses of Covishield have been given in India. He also noted a rise in heart attack-related deaths and sudden collapses post-Covid-19.
Serum Institute of India (SII), manufacturer of AstraZeneca’s COVID-19 vaccine Covishield in India, faces lawsuit as parents of Karunya, who died in July 2021 after receiving Covishield, plan to sue SII.
You might also be interested in – The Supreme Court ask Baba Ramdev and Balakrishna to appear in the Patanjali ‘misleading ads’ case
